Quarterly Update: Trends

in the Prescription
Medicines Market
IQVIA Quarterly Pharmaceutical Market
Outlook Newsletter, October 2024

© 2024. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
Contents
+ Growth drivers in prescription medicines
• Global view of the market
• Sales by therapy area for EU4&UK

+ In-depth global market dynamics

• Oncology value growth by indication
• Immunology trends and market drivers
• Biosimilar uptake rates by molecule

+ Trends in customer engagement and the promotional landscape

• By channel and country for EU4&UK

1
Growth drivers in
prescription medicines
• Global view of the market
• Sales by therapy area for EU4&UK

The following analysis has been developed using IQVIA’s MIDAS database. To learn more about the data, please visit
our MIDAS webpage.

© 2024. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
Global Rx market grows 9% YoY to reach $1.4 Tn, fuelled by specialty
biologics

Global Rx List price sales (Bn USD) Drivers of Global Growth 2023-24 (Bn USD)

+9% +119
(+9%)
+10% 1,426 1,426
+8% 2% 3%
1,307 5% +25
+7%
1,190 2% 2% (21%)
4% 13%
1,098 2%
1,029 2% 4% 2% 14% 4% +23
2% 4% 2% 14%
4% 2% 4% (19%)
15% 5% 22%
15%
5% 23% +23
5% (20%)
23%
23%
23%

+48
51% 52% (40%)
49% 50%
49%
1,307

2020 2021 2022 2023 2024 2023 Specialty Traditional Specialty Traditional 2024
Biologics Biologics Small Small
US Japan LATAM ROW Molecules Molecules
Europe APAC ME&A
Notes: Growth rates at constant exchange rates; data for all years is MAT Q2, COVID-19 vaccines & treatments excluded
Source: IQVIA EMEA Thought Leadership; IQVIA MIDAS MAT Q2 2024; Rx-only
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 3
1-year sales development of the global Rx market split by specialty,
biologics and generics – exclusive of COVID-19 Vx & Tx

Specialty and Traditional Biologics and Small Molecules Generics

(Bn USD) (Bn USD) (Bn USD)

1,426 1,426 326

309
1,307 1,307

54% 58%
55% 60%
84%
85%

46% 42%
45% 40%

15% 16%

2023 2024 2023 2024 2023 2024

Traditional Specialty Small molecules Biologics Traditional Gx Specialty Gx

Notes: Growth rates at constant exchange rates; data for all years is MAT Q2; generics defined as Innovation Insights non-original branded and unbranded generic
Source: IQVIA EMEA Thought Leadership; IQVIA MIDAS MAT Q2 2024; Rx-only
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 4
Global value is highly concentrated in a few top therapy areas –
exclusive of COVID-19 Vx & Tx
Therapy area sales (MAT Q2 2024) 2024 growth CAGR YoY
($ Bn) (2019-24) (2023-24)

Oncologics 46% 33% 5% 10% 3% $236 bn 29.9 13% 15%

~41% of
global Immunology 75% 16% 2% $178 bn 22.6 16% 15%
value
Antidiabetics 74% 10% 4% $176 bn 20.2 15% 13%

Antithrombotics 58% 25% 4% $62 bn 4.0 10% 7%

Respiratory Agents 62% 20% $54 bn 1.6 4% 3%

Antihypertensives 24% 30% 23% $42 bn 2.4 5% 6%

5% 12% 5%

HIV Antivirals 75% 17% $40 bn 2.2 5% 6%

Pain 26% 26% $40 bn 0.8 1% 2%

Mental Health 52% 20% 9% $36 bn

0.3 4% 1%

Antibacterials 20% 9% $33 bn -0.4 0% -1%

12% 8%

Anti-Obesity #21 US Europe Japan APAC LATAM ME&A ROW

5
Notes: Growth rates at constant exchange rates, data is MAT Q2
Source: IQVIA EMEA Thought Leadership; IQVIA MIDAS MAT Q2 2024; Rx-only
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 5
In the EU4+UK, specialty biologics led growth in the prescription drug
market- exclusive of COVID-19 Vx & Tx

YoY growth to Q2 2024, EU4+UK (Bn USD) EU4+UK: Therapy area sales (MAT Q2 2024)

+16 Oncologics $55 bn

(+8%)
214 Immunology $21 bn
+2
(14%) Antidiabetics $11 bn

+4 Antithrombotics $9 bn
(24%)
+1 Respiratory Agents $7 bn
(4%)
Antihypertensives $7 bn

Pain $6 bn
+9
(58%) Multiple Sclerosis $6 bn

All Other Respiratory $5 bn

198
HIV Antivirals $5 bn Anti-Obesity #59 2
2023 Specialty Traditional Specialty Traditional 2024
Biologics Biologics Small Small
Molecules Molecules France Italy UK
Germany Spain

Source: IQVIA EMEA Thought Leadership; IQVIA MIDAS MAT Q2 2024; Rx-only; all data is MAT Q2
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 6
In-depth global market
dynamics
• Oncology value growth by indication
• Immunology trends and market drivers
• Biosimilar uptake rates by molecule
The following oncology and immunology analyses have been developed using IQVIA’s Analytics Link and MIDAS
Disease databases respectively. For further insights on biosimilars, explore IQVIA’s MIDAS data.

© 2024. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
Breast cancer and NSCLC lead the oncology market and their growth is
forecast to accelerate
Solid tumours will drive oncology growth in the next 5 years
Growth dynamics of the top 15 tumour types Top tumour types
(Global, USD, 2019-29) (Global, 2024*)
35%
Historical 5y CAGR: 12% Small Cell Lung Tumour Sales CAGR
Growth Share
accelerating type (Bn USD) (2024-29)
30%
Breast 45 19% 21%
Solid Liver
NSCLC 29 12% 16%
25% Haem
Future 5y CAGR (2024*-29)

Ovarian Head & Neck Multiple

Breast 26 11% 10%
$10bn in Myeloma
20% 2024 Bladder
Prostate 21 9% 17%
NSCLC Prostate Future 5y CAGR: 16%
NHL Leukaemia 20 8% 12%
15% Kidney
Kidney 13 5% 14%
Colorectal
10% Gastric Colorectal 11 5% 14%
Multiple Myeloma
Leukaemia
NHL 11 5% 16%
5% Melanoma
Melanoma 10 4% 8%
Growth
decelerating Liver 5 2% 30%
0%
0% 5% 10% 15% 20% 25% 30% 35%

Historical 5y CAGR (2019-24*)

Notes: *Includes 2024 forecast data; NSCLC = Non-Small Cell Lung Cancer; NHL = Non-Hodgkin Lymphoma; Leukaemia data includes Chronic Myeloid Leukaemia, Chronic Lymphoid Leukaemia, Acute Myeloid
Leukaemia; constant exchange rate for USD; Source: IQVIA EMEA Thought Leadership, IQVIA Analytics Link, accessed Sep 2024
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 8
 The allergic inflammation market is growing at more than double the
rate of autoimmune
US continues to dominate in value market share and absolute growth contribution
Global immunology market performance Regional breakdown
(MAT Q2 2020-2024, Bn USD) (MAT Q2 2023-2024, USD)
180 178 70 $178bn $20.2bn
157 10%
160 $4bn $0.3bn
8% 60
140 136
$36bn $4.2bn
7% 50
117

Growth (YOY%)
120
Sales (Bn USD)

103 5%
100 4% 40

80 90% 30
92%
60 93% $125bn $14.1bn
95% 20
96%
40
10
20

0 0
MAT Q2 2020 MAT Q2 2021 MAT Q2 2022 MAT Q2 2023 MAT Q2 2024 MAT Q2 2024 Absolute Growth
Market Share MAT Q2 2023-24
Allergic inflammation Allergic inflammation growth US Japan LATAM ROW
Autoimmune Autoimmune growth Europe APAC ME&A
Notes: Total spending calculated at Constant Exchange Rate (CER)
Immunology market defined as following diseases and ATC3 codes: Rheumatoid Arthritis, Crohn’s Disease, Psoriasis, Psoriatic Arthritis, Hidradenitis Suppurativa, Ulcerative Colitis, Ankylosing Spondylitis and other
spondylarthritis, Allergic Asthma, Urticaria, Lupus, Nasal polyps, Esophagitis, Prurigo Nodularis, Alopecia Areata, Vitiligo. ATC3 codes: A7E, D5B, D5X, L4B, L4C, L4X, M1C
Source: IQVIA EMEA Thought leadership; IQVIA MIDAS Disease MTH 06 2024
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 9
Rate of uptake of biosimilars has accelerated as stakeholders become
increasingly comfortable with biosimilars
European biosimilar market averaging 30% after Q4 and 50% after Q8
Europe biosimilar uptake rates US biosimilar uptake rates
(quarters since launch, Treatment Days) (quarters since launch, Treatment Days)

Launch Launch
Dates Dates
100% 100%
Bevacizumab Jul 20
Adalimumab Feb 23
80% Adalimumab Oct 18 80%
Rituximab Nov 19

Pegfilgrastim Oct 18 60%

60%
Trastuzumab Jul 19

Trastuzumab Apr 18
40% 40% Bevacizumab Jul 19

Rituximab Apr 17
Pegfilgrastim Jul 18
20% 20%
Etanercept Mar 16
Infliximab Nov 16
0% Infliximab Oct 13 0%
Q0 Q2 Q4 Q6 Q8 Q10 Q12 Q0 Q2 Q4 Q6 Q8 Q10 Q12

Notes: Includes subcutaneous formulations for rituximab, trastuzumab and infliximab

Source: IQVIA EMEA Thought Leadership; IQVIA MIDAS QTR Jun 2024
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 10
The introduction of new biosimilars continue to have varied adoption
across Europe & US
Eculizumab biosimilar uptake Ranibizumab biosimilar uptake
(Months from launch, EU, treatment days) (Months from launch, EU&US, treatment days)
60% 100%
France
80%
Germany Germany
40%
Italy 60%
Italy
Spain
20% 40%
UK Spain
20%
UK
0% 0%
M0 M2 M4 M6 M8 M10 M12 US
M0 M2 M4 M6 M8 M10 M12
Natalizumab biosimilar uptake Tocilizumab biosimilar uptake
(Months from launch, EU, treatment days) (Months from launch, EU, treatment days)
100% France 100% France
80%
Germany 80% Germany
60% Italy
Italy 60%
40% Spain
Spain 40%
20% UK
UK 20%
0% US
M0 M2 M4 M6 M8 M10 M12 0%
M0 M2 M4 M6 M8 M10 M12
Notes: Selected countries with notable sales
Source: IQVIA EMEA Thought Leadership; IQVIA MIDAS MTH June 2024
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 11
Trends in customer
engagement and the
promotional landscape
By channel and country for EU4&UK

The following analysis has been developed using IQVIA’s ChannelDynamics database. To learn more please visit our
ChannelDynamics webpage.

© 2024. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
 Interactions between sales reps and HCPs are predominantly F2F,
especially in Italy and France
Interactive contact volume is particularly high in Italy but low in the UK
1:1 interactive contact volume by channel (Q2 2022 – Q2 2024)

Germany France Italy Spain UK

13 13 13 13 13
Number of contacts per quarter (millions)

12 12 12 12 12
11 11 11 11 11
10 10 10 10 10
9 9 9 9 9
8 8 8 8 8
7 7 7 7 7
6 2019 6 6 6 6
benchmark
5 5 5 5 5
4 4 4 4 4
3 3 3 3 3
2 2 2 2 2
1 1 1 1 1
0 0 0 0 0
Q2 Q4 Q2 Q4 Q2 Q2 Q4 Q2 Q4 Q2 Q2 Q4 Q2 Q4 Q2 Q2 Q4 Q2 Q4 Q2 Q2 Q4 Q2 Q4 Q2
2022 2022 2023 2023 2024 2022 2022 2023 2023 2024 2022 2022 2023 2023 2024 2022 2022 2023 2023 2024 2022 2022 2023 2023 2024

F2F Remote
Notes: Only interactive channels included; F2F includes F2F detailing and F2F meetings; Remote includes telephone detailing, e-detailing (live), e-meetings (live); contact volume in contact numbers
Source: IQVIA EMEA Thought Leadership; IQVIA ChannelDynamics MAT Q2 2024 (accessed Sep 2024)
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 13
Promotional volume is still below pre-pandemic in France due to a fall in F2F
interactions, although F2F still has the biggest share
Share of promoters in France is <25%, similar to pre-pandemic
Share of promotional volume NPS Category share
+13% -16%
-8%
15.9 M
15.3 M YTD Q2 2019 24% 38% 38%
10% -20%
12% 14.1 M
13.4 M
11% YTD Q2 2020 22% 34% 44%
8% +5%
Postal mail
27% 11.2 M Emails
42% 10.7 M 6%
Digital
9% YTD Q2 2021 22% 35% 43%
Remote
2% 1% 47% 45%
F2F
43%
1% 38%
5% YTD Q2 2022 21% 34% 45%
1%
1% 4%
6% 3% 1% 4% 0%
59% YTD Q2 2023 23% 40% 37%
42%
43% 50% 47%
35%
YTD Q2 2024 24% 36% 40%

YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2

2019 2020 2021 2022 2023 2024 Promoters Passives Detractors

Notes: Refer to appendix for channel details; YTD data is until Q2 for 2019, 2020, 2021, 2022, 2023 and 2024; NPS – Net Promoter Score – based on HCPs’ responses to ‘Overall, how likely would you be to recommend
this interaction to a colleague?’ (Promoters: 9-10; Passives: 7-8; Detractors: 0-6) Source: IQVIA Global ChannelDynamics
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 14
Promotional volume is below pre-pandemic levels in Germany, and postal
mail continues to hold the biggest share
The number of promoters is low in Germany, amounting to 22% of interactions
Share of promotional volume NPS Category share
+7% -16%
+4% 32.1 M
YTD Q2 2019 25% 29% 46%
30.0 M
28.9 M -2%
-3%
27.0 M
26.3 M
25.4 M YTD Q2 2020 23% 29% 48%

55%
53% 57% Postal mail
YTD Q2 2021 22% 29% 49%
53% 49% 45% Emails
Digital
Remote
F2F YTD Q2 2022 24% 26% 49%

10%
1% 0% 24%
19% 22% 26% 31%
YTD Q2 2023 23% 29% 48%
1% 1%
4% 1% 4% 1%
2% 1%
35% 7% 3%

19% 21% 21% 20% YTD Q2 2024 22% 33% 46%

13%

YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2

2019 2020 2021 2022 2023 2024 Promoters Passives Detractors

Notes: Refer to appendix for channel details; YTD data is until Q2 for 2019, 2020, 2021, 2022, 2023 and 2024; NPS – Net Promoter Score – based on HCPs’ responses to ‘Overall, how likely would you be to recommend
this interaction to a colleague?’ (Promoters: 9-10; Passives: 7-8; Detractors: 0-6) Source: IQVIA Global ChannelDynamics
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 15
Promotional volume is still below pre-pandemic levels in Italy, and F2F
interactions continue to account for the vast majority
The number of promoters in Italy is high and increasing, currently at 41% of interactions
Share of promotional volume NPS Category share
-43%
28.0 M
YTD Q2 2019 38% 43% 19%
1% 0%
2%
2%

+27% -5% YTD Q2 2020 37% 43% 20%

0% 0%
20.3 M
0% 19.3 M 19.4 M 19.4 M
7% 1% 1% 1%
2% 8% 9% Postal mail
6% 12% YTD Q2 2021 39% 42% 19%
2% 2%
16.1 M 4% 3% 1% Emails
1% 4%
10% Digital
3% Remote
96%
13% YTD Q2 2022 40% 42% 18%
F2F

84% 86% 84% 82% YTD Q2 2023 40% 42% 18%

74%

YTD Q2 2024 41% 42% 17%

YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2

2019 2020 2021 2022 2023 2024 Promoters Passives Detractors

Notes: Refer to appendix for channel details; YTD data is until Q2 for 2019, 2020, 2021, 2022, 2023 and 2024; NPS – Net Promoter Score – based on HCPs’ responses to ‘Overall, how likely would you be to recommend
this interaction to a colleague?’ (Promoters: 9-10; Passives: 7-8; Detractors: 0-6) Source: IQVIA Global ChannelDynamics
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 16
Promotional volume has remained constant in Spain for recent years, and
F2F interactions continue to hold the biggest share
Promoters see a rapid increase to 50% in Spain, while detractors have fallen to just 14%
Share of promotional volume NPS Category share
-19%
16.4 M 0%
+9% +1% 0% YTD Q2 2019 36% 42% 22%
4% 1%
2% 14.5 M 14.7 M 14.7 M 14.8 M
5% 1% 0% 0%
1%
13.3 M 13%
15% 15% 18% YTD Q2 2020 37% 40% 23%
1% Postal mail
13% 5% 4% Emails
7% 2%
6% 13% 10% Digital
10%
Remote YTD Q2 2021 39% 40% 21%
F2F
28%
28%

88% YTD Q2 2022 41% 39% 20%

68% 70% 69%

YTD Q2 2023 49% 36% 15%
52% 49%

YTD Q2 2024 50% 36% 14%

YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2

2019 2020 2021 2022 2023 2024 Promoters Passives Detractors

Notes: Refer to appendix for channel details; YTD data is until Q2 for 2019, 2020, 2021, 2022, 2023 and 2024; NPS – Net Promoter Score – based on HCPs’ responses to ‘Overall, how likely would you be to recommend
this interaction to a colleague?’ (Promoters: 9-10; Passives: 7-8; Detractors: 0-6) Source: IQVIA Global ChannelDynamics
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 17
Promotional volume is above pre-pandemic levels in UK, and email is now
the most commonly-used channel
The number of promoters in the UK is low but gradually increasing, currently at 24%
Share of promotional volume NPS Category share

+37%

15.5 M YTD Q2 2019 21% 38% 41%

22%
+2% -1% YTD Q2 2020 20% 38% 42%
+10%
-3% Postal mail
11.1 M 11.3 M 11.3 M
Emails
10.4 M 10.1 M Digital YTD Q2 2021 22% 37% 41%
25% 23%
28% Remote
37% F2F
37%
54%
YTD Q2 2022 23% 37% 40%

53% 54%
30% 51%
42% YTD Q2 2023 24% 39% 37%

3% 1% 3%
3% 7%
2% 3% 2%
7% 10% 8%
29% YTD Q2 2024 24% 40% 37%
14% 13%
13% 10% 13%
4%
YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2
2019 2020 2021 2022 2023 2024 Promoters Passives Detractors

Notes: Refer to appendix for channel details; YTD data is until Q2 for 2019, 2020, 2021, 2022, 2023 and 2024; NPS – Net Promoter Score – based on HCPs’ responses to ‘Overall, how likely would you be to recommend
this interaction to a colleague?’ (Promoters: 9-10; Passives: 7-8; Detractors: 0-6) Source: IQVIA Global ChannelDynamics
IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 18
 F2F visits, in-person conferences and emails uphold the top three
positions as the most preferred channels over time
Aggregated EU4+UK and US channel preference splits
HCPs’ preferred mixture of channels (2021-24)
100%

90% 2024 IQVIA Channel

80%
Preference Survey
Analysis
70%
9% 9%
60% 10% 14% • 38 Countries
11%
18%
50% 16% 16% • 32,000+ HCPs
40%

30% Watch out for a blog on

51%
20% 44% 41% 41%
channel preference –
available soon on our
10%
webpage.
0%
2021 2022 2023 2024
F2F 1:1 visit In-person conference Email Remote conferences
On-demand presentations Post / mail 1:1 video call Instant message/text
Telephone Podcasts Online resources
Source: IQVIA EMEA Thought Leadership; Channel Preference Survey 2024 19
Stay ahead of the curve

To receive updates from

Thought Leadership on key
market trends, sign up here
Appendix
Definitions for regional and channel
groupings

© 2024. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
Regional grouping definitions

Region Countries included

US US
Austria, Belarus, Belgium, Bosnia, Bulgaria, Croatia, Czech Republic, Denmark,
Estonia, Finland, France, Germany, Greece, Hungary,
Europe Ireland, Italy, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Poland,
Portugal, Romania, Russia, Serbia, Slovakia, Slovenia,
Spain, Sweden, Switzerland, UK, Ukraine
Japan Japan
Australia, Bangladesh, China, Hong Kong, India, Indonesia, Kazakhstan, Korea,
APAC Malaysia, New Zealand, Pakistan, Philipines,
Singapore, Sri Lanka, Taiwan, Thailand, Vietnam

Argentina, Brazil, C. America, Chile, Colombia, Dominican Republic, Ecuador,

LATAM
Mexico, Peru, Puerto Rico, Uruguay, Venezuela

Algeria, Egypt, Fr. W. Africa, Jordán, Kuwait,

ME&A
Lebanon, Morocco, S. Africa, Saudi Arabia, Tunisia, Turkey, UAE

ROW Canada

IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 22

Channel grouping definitions
Definitions for the five customer engagement slides for individual countries
Interaction type Channels included

F2F - Detailing
F2F
F2F - Meetings/Events
Remote - Detailing with Rep (Telephone)
Remote Remote - Detailing with Rep (Online)
Remote - Meetings/Events (Live)
Digital - Detailing (Automated)
Digital - Meetings/Events
Digital
Digital - Instant Messaging/Texting
Digital - Podcast

Emails Digital - E-Mailing

Postal mail Mailing (Postal)

IQVIA Quarterly Pharmaceutical Market Outlook Newsletter, Oct 2024 23